Fertomid 25mg Tablet(Clomiphene 25mg)

Description

Fertomid 25mg Tablet (Clomiphene 25mg) — Complete Clinical and Patient Information Guide

Product Overview

Fertomid 25mg Tablet (Clomiphene 25mg) contains Clomiphene Citrate 25mg as its active pharmaceutical ingredient, belonging to the selective oestrogen receptor modulator (SERM) — ovulation induction agent. It is clinically indicated for anovulatory and oligo-ovulatory infertility including polycystic ovary syndrome (PCOS); male infertility (off-label for hypogonadotrophic hypogonadism). This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Fertomid 25mg provides clomiphene citrate — the standard first-line pharmacological ovulation induction agent for anovulatory infertility, with over 60 years of clinical use and an established evidence base in PCOS and other anovulatory conditions.

About Fertomid 25mg and Its Active Ingredient

Clomiphene Citrate 25mg is the pharmacologically active compound in Fertomid 25mg, a well-established cardiovascular or therapeutic agent with a clinical evidence base developed across decades of research. All cardiovascular and hormonal pharmacotherapy requires physician supervision — drug interactions, contraindications, and dose optimisation decisions require professional medical assessment. Never start, change, or stop these medications without consulting your prescribing physician.

Mechanism of Action

Clomiphene citrate is a selective oestrogen receptor modulator (SERM) used to induce ovulation in anovulatory or oligo-ovulatory women. It competitively blocks oestrogen receptors in the hypothalamus and anterior pituitary, preventing endogenous oestrogen from exerting its normal negative feedback on gonadotropin-releasing hormone (GnRH) and gonadotropins (FSH, LH). In response to perceived low oestrogen activity, the hypothalamo-pituitary axis releases increased pulses of GnRH, driving elevated FSH and LH secretion from the pituitary. This pituitary FSH surge stimulates ovarian follicle recruitment and maturation, and the subsequent LH surge triggers ovulation — restoring ovulatory cycles in women with anovulatory infertility including PCOS. Clomiphene’s anti-oestrogenic effects on the endometrium and cervical mucus (reducing endometrial receptivity) are the main adverse effects limiting its use beyond 6 cycles.

Clinical Indications

Fertomid 25mg Tablet (Clomiphene 25mg) is indicated for:

• Primary indication: anovulatory and oligo-ovulatory infertility including polycystic ovary syndrome (PCOS); male infertility (off-label for hypogonadotrophic hypogonadism)
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of therapy.

Dosage and Administration

Ovulation induction: 25mg once daily for 5 consecutive days starting on day 2–5 of the menstrual cycle (or day 2–5 after progesterone-induced withdrawal bleed). If ovulation does not occur, increase dose to 100mg for subsequent cycle. Maximum recommended dose: 150mg/day. Maximum recommended duration: 6 cycles. Use under specialist gynaecological/fertility supervision with cycle monitoring (ultrasound, LH surge).

Who Should Use Fertomid 25mg

Fertomid 25mg is appropriate for patients confirmed by a qualified healthcare professional to have the conditions listed in the indications section, in whom this specific formulation is clinically appropriate following benefit-risk assessment with no absolute contraindications.

Contraindications

Ovarian cysts or ovarian enlargement (unrelated to polycystic ovaries — treat or exclude before starting). Hepatic disease or dysfunction. Unexplained uterine bleeding. Oestrogen-dependent tumours (contraindicated). Pregnancy (if pregnancy has occurred). Visual disturbances from previous clomiphene course.

Drug Interactions

No major pharmacokinetic drug interactions. Concurrent gonadotrophins (FSH) for controlled ovarian stimulation: carefully supervised by fertility specialist. Anti-oestrogens: additive hypothalamic-pituitary stimulation.

A complete medication review is essential before initiating Fertomid 25mg. Cardiovascular and hormonal drugs have numerous clinically significant interactions that can be dangerous if unidentified. Patients must inform all healthcare providers of their complete medication list.

Adverse Effects

Hot flushes (most common — 10–15%). Mood changes, depression, and irritability. Ovarian enlargement (5–14% — monitor with ultrasound). Multiple pregnancy risk (twin rate ~8%, triplet rate ~1% — counsel on risk). Ovarian hyperstimulation syndrome (OHSS) — rare but serious with clomiphene. Visual disturbances (blurred vision, scotomata — rare; if occurs, stop and do not resume). Endometrial thinning and hostile cervical mucus (anti-oestrogenic effects on reproductive tissue).

Special Population Considerations

Specialist supervision required: Clomiphene therapy for ovulation induction should only be prescribed and monitored by a gynaecologist or fertility specialist. Cycle monitoring with ultrasound to assess follicular response and prevent OHSS is important. Multiple pregnancy risk: Patients must be counselled that clomiphene approximately doubles the risk of twin pregnancy compared to spontaneous conception — multiple pregnancy carries significant maternal and foetal risks. Duration limit: Do not exceed 6 treatment cycles. Long-term clomiphene (>12 cycles) has been associated with increased ovarian cancer risk in some studies. If pregnancy has not occurred after 6 cycles, alternative fertility treatments should be considered. PCOS use: Clomiphene is first-line pharmacological ovulation induction in PCOS — approximately 75–80% of PCOS women ovulate on clomiphene, and approximately 40–50% conceive within 6 cycles.

Storage

Store Fertomid 25mg at room temperature (15–25°C) away from direct sunlight, heat, and moisture. Keep in original packaging. Maintain out of reach of children. Do not use beyond expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop cardiovascular medications abruptly without medical advice.

Q: How many cycles of clomiphene should I try before other treatments?
A: Standard guidelines recommend a maximum of 3–6 ovulation induction cycles with clomiphene before considering alternative treatments. If ovulation is occurring (confirmed by ultrasound or progesterone test) but pregnancy has not occurred after 6 ovulatory cycles, the fertility treatment pathway should be escalated — typically to clomiphene + intrauterine insemination (IUI) or gonadotrophin injections with IVF. Continuing beyond 6 cycles adds incremental risk without proportionate benefit.

Evidence Base and Clinical Guidelines

The active ingredient in Fertomid 25mg has been evaluated in landmark randomised controlled trials and is supported by international cardiovascular guidelines from the ESC, ACC/AHA, NICE, and national specialist bodies. Evidence-based cardiovascular pharmacotherapy has transformed outcomes for hypertension, angina, heart failure, and arrhythmia management. GMP-compliant manufacturing ensures consistent product quality and safety.

Cardiovascular Disease Management Context

Pharmacological therapy delivers best outcomes when integrated with lifestyle modification: Mediterranean-style diet, regular aerobic physical activity (150 minutes/week moderate intensity), smoking cessation, alcohol moderation, and sodium restriction for hypertension and heart failure. The combination of optimal pharmacotherapy and sustained lifestyle change produces cardiovascular risk reduction far exceeding either approach alone. Regular follow-up monitoring — blood pressure recording, ECG, renal function and electrolytes — is essential to optimise therapy and detect adverse effects early.

Fixed-dose combination antihypertensive tablets — such as many products in this range — significantly improve treatment adherence, which is the single most common reason for inadequate blood pressure control in treated hypertensive patients. Multiple studies demonstrate that every 10mmHg sustained reduction in systolic blood pressure reduces major cardiovascular event risk by approximately 20%, providing strong motivation for achieving and maintaining blood pressure targets.

Patient Counselling Key Points

• Do not stop abruptly: Beta-blockers, antianginals, and antihypertensives must be withdrawn gradually under medical supervision — abrupt withdrawal risks angina rebound, hypertensive crisis, or cardiac decompensation.
• Monitor blood pressure: Home blood pressure monitoring at the same time daily provides valuable data for dose optimisation — target below 130/80 mmHg in most guidelines for hypertensive patients with cardiovascular disease.
• Carry medication list: All patients on cardiovascular medications should carry a complete medication list for surgical, dental, and emergency care encounters where drug interactions are critical.

Gynaecological and Parasitological Considerations

For clomiphene citrate (ovulation induction): Female infertility affects approximately 1 in 6 couples globally. Anovulation — the failure to release an egg — accounts for approximately 30–40% of female infertility. PCOS (polycystic ovary syndrome) is the most common cause of anovulatory infertility, affecting 8–12% of women of reproductive age. Clomiphene citrate remains the first-line pharmacological treatment for ovulation induction in anovulatory women, with decades of evidence supporting its safety and efficacy. For women who do not respond to clomiphene (approximately 20–25% of PCOS patients), subsequent options include letrozole (showing evidence of higher live birth rates in PCOS), gonadotrophin injections, and assisted reproductive technologies (IVF/ICSI).

For albendazole (anthelmintic): Helminthic infections affect approximately 1.5 billion people globally, predominantly in low- and middle-income countries. Soil-transmitted helminths (Ascaris, hookworm, Trichuris) account for the majority of cases, causing anaemia, malnutrition, impaired cognitive development, and reduced work productivity. WHO recommends periodic deworming with albendazole or mebendazole as a public health intervention in endemic areas. For individual clinical treatment, the choice between single-dose treatment for intestinal helminths and prolonged courses for systemic infections requires accurate diagnosis and appropriate specialist guidance.

For liothyronine (thyroid hormone): Hypothyroidism affects approximately 2–5% of adults globally, with subclinical hypothyroidism occurring in an additional 4–8%. The vast majority of hypothyroid patients achieve adequate thyroid function with levothyroxine (T4) monotherapy. The question of adding T3 (liothyronine) for patients who remain symptomatic despite normal TSH on optimal T4 is an active area of clinical debate — some patients have impaired peripheral T4-to-T3 conversion, and a subset appears to benefit from combination T4+T3 therapy. This requires specialist endocrinological assessment and careful, individualised management.

Evidence Base and Quality Standards

All active ingredients in this product range have been evaluated in randomised controlled trials, systematic reviews, and regulatory submissions reviewed by competent health authorities. GMP-compliant manufacturing ensures consistent product quality across all batches. Patients should obtain prescription medications only from licensed pharmacies with valid prescriptions.

Blood Pressure Targets and Monitoring

Current major cardiovascular guidelines (ESC/ESH 2023, ACC/AHA 2017) recommend the following blood pressure targets for hypertensive patients: general adult population with uncomplicated hypertension, target below 130/80 mmHg; patients aged ≥65 years, target 130–139/70–79 mmHg (avoiding over-treatment which may paradoxically increase risk through J-curve phenomena); patients with CKD and proteinuria, target below 130/80 mmHg; patients with coronary artery disease and stable angina, target 130/80 mmHg or lower; patients with diabetes mellitus, target below 130/80 mmHg.

Home blood pressure monitoring (HBPM) and 24-hour ambulatory BP monitoring (ABPM) are recommended over office BP measurements alone for treatment decisions — office measurements overestimate true BP (white coat hypertension) in approximately 15–30% of patients and underestimate it (masked hypertension) in others. ABPM or HBPM provides more accurate cardiovascular risk assessment and better treatment optimisation.

Patient Counselling Summary

Key points for all patients on antihypertensive and cardiovascular medications: Take medications at the same time daily for consistent drug levels. Never skip doses — cardiovascular medications require consistent daily use for their full protective benefit. Never stop medications abruptly — particularly beta-blockers (rebound angina/hypertension risk) and antianginal drugs. Monitor blood pressure at home at the same time each day in a relaxed, seated position after 5 minutes rest. Report side effects promptly — many can be managed with dose adjustment or substitution rather than discontinuation. Maintain lifestyle modifications: salt restriction (below 6g/day), DASH or Mediterranean diet, regular moderate-intensity aerobic exercise (150 minutes/week), smoking cessation, and alcohol moderation. Attend all scheduled follow-up appointments for blood pressure recording, ECG, and biochemical monitoring as indicated.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It does not replace professional medical advice from a qualified physician, cardiologist, endocrinologist, gynaecologist, or pharmacist. Drug therapy decisions must be individualised. Self-diagnosis and self-treatment of cardiovascular, hormonal, and parasitic conditions can be dangerous. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.